Fazio ND - Search Results

1

SARS-CoV2 Vaccination Adverse Events Trend in Italy: A Retrospective Interpretation of the Last Year (December 2020-September 2021).

Fazio ND, Delogu G, Bertozzi G, Fineschi V, Frati P. Fazio ND, et al. Vaccines (Basel). 2022 Jan 30;10(2):216. doi: 10.3390/vaccines10020216. Vaccines (Basel). 2022. PMID: 35214674 Free PMC article.

2

Cannabinoids and Brain Damage: A Systematic Review on a Frequently Overlooked Issue.

Scopetti M, Morena D, Manetti F, Santurro A, Fazio ND, D'Errico S, Padovano M, Frati P, Fineschi V. Scopetti M, et al. Among authors: fazio nd. Curr Pharm Biotechnol. 2023;24(6):741-757. doi: 10.2174/1389201023666220614145535. Curr Pharm Biotechnol. 2023. PMID: 35702797

3

Considerations on some court judgments concerning the compulsory vaccination for healthcare workers in Italy.

Morena D, Fazio ND, Delogu G, Padovano M, Frati P. Morena D, et al. Among authors: fazio nd. Med Leg J. 2022 Dec;90(4):241-243. doi: 10.1177/00258172221118409. Epub 2022 Sep 19. Med Leg J. 2022. PMID: 36117405 No abstract available.

4

Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs): The Role of Checkpoint Inhibitors.

Arrivi G, Fazio N. Arrivi G, et al. Curr Cancer Drug Targets. 2022 Aug 15;22(8):629-638. doi: 10.2174/1568009622666220114124335. Curr Cancer Drug Targets. 2022. PMID: 35034595

5

Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?

Fazio N, de Braud F, Delle Fave G, Öberg K. Fazio N, et al. Ann Oncol. 2007 Jan;18(1):13-19. doi: 10.1093/annonc/mdl144. Epub 2006 Jun 23. Ann Oncol. 2007. PMID: 16798833 Free article. Review.

6

Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours.

Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D, Crosta C. Ravizza D, et al. Dig Liver Dis. 2007 Jun;39(6):537-43. doi: 10.1016/j.dld.2007.01.018. Epub 2007 Apr 11. Dig Liver Dis. 2007. PMID: 17433795

7

Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives.

Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G. Capurso G, et al. Crit Rev Oncol Hematol. 2009 Nov;72(2):110-24. doi: 10.1016/j.critrevonc.2009.01.008. Epub 2009 Feb 26. Crit Rev Oncol Hematol. 2009. PMID: 19249226 Review.

8

Chemotherapy in pancreatic adenocarcinoma.

Squadroni M, Fazio N. Squadroni M, et al. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):386-94. Eur Rev Med Pharmacol Sci. 2010. PMID: 20496553 Review.

9

Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M. Panzuto F, et al. Neuroendocrinology. 2012;96(1):32-40. doi: 10.1159/000334038. Epub 2011 Dec 28. Neuroendocrinology. 2012. PMID: 22205326

10

Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.

Fazio N, Spada F, Giovannini M. Fazio N, et al. Cancer Treat Rev. 2013 May;39(3):270-4. doi: 10.1016/j.ctrv.2012.06.009. Epub 2012 Jul 20. Cancer Treat Rev. 2013. PMID: 22819619 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters